论文部分内容阅读
目的:研究分析干扰素联合布地奈德+异丙托溴铵雾化吸入治疗小儿病毒性喘息型支气管肺炎的临床效果。方法:选取我院在2015年4月~2016年4月收治的68例小儿病毒性喘息型支气管肺炎患者,随机分成常规组与对照组,每组各34例。常规组患儿予病毒性喘息型支气管肺炎常规治疗上加用布地奈德+异丙托溴铵雾化吸入,治疗组在常规组基础上联合干扰素治疗,治疗1周后,观察比较2组患者的临床疗效、临床症状的变化、住院天数以及治疗过程中的不良反应。结果:两组患儿在性别、年龄、体重及BMI上差异无统计学意义;治疗组临床症状消失时间及平均住院天数相比较常规组来说,均明显较少;治疗1周后治疗组总有效率(97.1%)明显高于常规组总有效率(67.6%);两组患儿治疗过程中均未出现严重不良反应事件,且不良反应发生率相似,两组比较无统计学意义。结论:临床上使用干扰素联合布地奈德+异丙托溴铵雾化吸入治疗小儿病毒性喘息型支气管肺炎可短时间内明显改善患儿临床症状,缩短患儿住院时间,并有较高的临床疗效且无明显不良反应,可考虑作为临床上治疗小儿病毒性喘息型支气管肺炎的首选治疗方案。
OBJECTIVE: To study the clinical effect of interferon combined with budesonide and ipratropium bromide in the treatment of infantile viral wheezing bronchopneumonia. Methods: A total of 68 pediatric patients with viral respiratory bronchial pneumonia who were admitted to our hospital from April 2015 to April 2016 were randomly divided into routine group and control group, 34 cases in each group. The conventional group of children with viral wheezing bronchopneumonia routine therapy plus budesonide + ipratropium bromide inhalation, the treatment group in combination with conventional interferon therapy, after 1 week of treatment, compared the two groups The patient’s clinical efficacy, changes in clinical symptoms, days of hospitalization and adverse reactions in the course of treatment. Results: There was no significant difference in gender, age, body weight and BMI between the two groups. The disappearance time and the average length of stay in the treatment group were significantly less than those in the conventional group. After 1 week of treatment, The effective rate (97.1%) was significantly higher than that of the conventional group (67.6%). There were no serious adverse events during the course of treatment in both groups, and the incidence of adverse reactions was similar. There was no significant difference between the two groups. Conclusion: The clinical use of interferon combined with budesonide + ipratropium bromide inhalation therapy in children with viral wheezing bronchopneumonia can significantly improve the clinical symptoms of children in a short time, shorten the hospitalization of children, and have a higher Clinical efficacy and no obvious adverse reactions, can be considered as the treatment of pediatric viral wheezing bronchial pneumonia, the preferred treatment options.